ReNerve has reported its strongest quarter yet, with sales climbing to $584,000 as the medical device company expands across Asia-Pacific. The growth came alongside a secured funding drawdown, leaving the company with $1.62 million in cash but continued negative operating cash flow.
Biotron has appointed Glenn Gilbert as chief executive and executive director, bringing more than two decades of pharmaceutical, medical device and diagnostics experience to the company’s SedRx and antiviral programs. His package combines a $250,000 salary with up to 100 million performance-based options and $230,000 in milestone-linked cash bonuses.